Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SLP
SLP logo

SLP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Simulations Plus Inc (SLP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
14.840
1 Day change
1.92%
52 Week Range
36.450
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Simulations Plus Inc (SLP) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and optimistic revenue forecast outweigh the neutral trading sentiment and lack of immediate trading signals. The stock's current pre-market price of $14.55 is near its pivot level, presenting a reasonable entry point.

Technical Analysis

The MACD is positive at 0.237, indicating bullish momentum, although it is contracting. RSI is neutral at 52.692, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its pivot level of $14.17, with key resistance at $15.352 and support at $12.987.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
6

Positive Catalysts

  • Partnership with Lonza and the FDA to enhance regulatory confidence in drug products.

  • Strong Q2 FY2026 financial results with 8% revenue growth, 47.53% net income growth, and a 46.67% EPS increase.

  • Optimistic full-year revenue forecast of $79 million to $82 million.

Neutral/Negative Catalysts

  • Analyst downgrade by TD Cowen, reducing the price target to $16 from $

  • Neutral sentiment from hedge funds and insiders, with no significant trading trends.

Financial Performance

In Q2 FY2026, revenue increased by 8.29% YoY to $24.29 million, net income grew by 47.53% YoY to $4.535 million, and EPS rose by 46.67% YoY to $0.22. Gross margin improved significantly by 25.15% YoY to 73.24%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

TD Cowen downgraded the price target from $19 to $16, maintaining a Hold rating. Despite this, the firm acknowledged strong Q2 results driven by development software and services.

Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
Wall Street analysts forecast SLP stock price to rise
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 14.560
sliders
Low
19
Averages
19
High
19
Current: 14.560
sliders
Low
19
Averages
19
High
19
TD Cowen
Hold
downgrade
$19 -> $16
AI Analysis
2026-04-10
Reason
TD Cowen
Price Target
$19 -> $16
AI Analysis
2026-04-10
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Simulations Plus to $16 from $19 and keeps a Hold rating on the shares. The firm said they reported solid Q2 results driven by Development software and services strength despite some commercial-stage lightness.
TD Cowen
Hold
maintain
$16 -> $19
2026-01-08
Reason
TD Cowen
Price Target
$16 -> $19
2026-01-08
maintain
Hold
Reason
TD Cowen raised the firm's price target on Simulations Plus to $19 from $16 and keeps a Hold rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SLP
Unlock Now

People Also Watch